Tartu-based Better Medicine, an Estonian MedTech startup, secured €1 million in pre-Seed funding. Soulmates Ventures led the round. Specialist VC, UT Ventures, and several angel investors also participated. This funding supports the expansion of its AI-powered diagnostic tools.
Better Medicine develops AI-powered diagnostic tools for radiology. Its BMVision platform integrates into radiologists' workflows. The system detects and measures oncological findings, initially focusing on kidney lesions. This new capital will support European commercial rollout, advancing MedTech innovation and strengthening Better Medicine's AI funding base.
Radiology departments face increasing scan volumes and professional shortages, a challenge also addressed by companies like AI HealthScan. Globally, an estimated 12 million hours annually are spent on manual lesion measurements. Better Medicine's clinically validated AI models assist radiologists, driving AI in healthcare forward, similar to other companies seeking AI funding for medical solutions.
Advancing AI in Radiology Diagnostics
BMVision Kidney recently received CE certification as a Class IIa medical device. This makes it the first CE-certified, AI-based kidney cancer detection tool compliant with EU MDR, distinguishing it from solutions offered by Precision Diagnostics AI. Clinical evaluations show radiologists using BMVision achieved up to 52% time savings. The system also demonstrated a 99.2% detection rate.
The company plans to expand its product portfolio to cover additional organs and metastatic sites. It will launch clinical pilots in the U.S. tailored to FDA study requirements, a common strategy for European startups entering the US market. Better Medicine also engages with health insurance providers in Estonia. This demonstrates cost-benefit outcomes for sustainable market adoption. Including grants, Better Medicine has secured nearly €6 million in total funding.
